Clinical trials recruiting patients with MF
| Target ClinicalTrials.gov identifier . | Molecule . | Mechanism of action . | Phase . | Population on study . |
|---|---|---|---|---|
| Apoptosis | ||||
| NCT04562870 | Selinexor | Selective inhibition of nuclear export | 2 | JAK1/2i-experienced n ≈ 112 |
| NCT03627403 (ESSENTIAL) | Selinexor | Selective inhibition of nuclear export | 2 | JAK1/2i-experienced n ≈ 56 |
| NCT04562389 | Selinexor + RUX | Selective inhibition of nuclear export + JAK inhibition | 1/2 | JAKi-naïve n ≈ 237 |
| Microenvironment | ||||
| NCT03895112 | AVID200 | TGFβ1/3 trap | 1 | RUX-experienced and RUX-ineligible n = 22 |
| NCT04676529 | PXS-5505 | Pan LOX inhibition | 1/2a | RUX/FEDR-naïve and RUX/FEDR -experienced n ≈ 24 |
| NCT04679870 | GB2064 | LOXL-2 inhibition | 2a | JAKi-naïve and JAKi-experienced n ≈ 21 |
| NCT05467800 (MPN-RC 122) | Canakinumab | IL-1β targeting | 2 | RUX/FEDR ineligible, resistant, relapsed or intolerant n = 26 |
| NCT05037760 (KER050-MF-301) | KER050 ± RUX | ActRIIA ligand trap ± JAK inhibition | 2 | JAKi experienced or ineligible (monotherapy) or in stable RUX dose (combination) n = 110 |
| NCT04455841 | INCB000928 ± RUX | ALK2 inhibition ± JAK inhibition | 1/2 | RUX-experienced or ineligible (monotherapy) or in stable RUX dose (combination) n ≈ 100 TD or symptomatic anemia |
| NCT05320198 | DISC-0974 | Hemojuvelin targeting | 1b/2a | Patients with anemia JAKi-naïve and JAKi-experienced n = 56 |
| Epigenetics | ||||
| NCT04480086 | Mivebresib monotherapy, ± RUX or ± navitoclax | BET inhibition ± JAK inhibition ± BCL inhibition | 1b | JAKi-naïve or JAKi-experienced + BETi-naïve n ≈ 130 |
| NCT04454658 | ABBV-744 monotherapy, ± RUX or ± navitoclax | BET inhibition ± JAK inhibition ± BCL inhibition | 1b | JAKi-naïve or JAKi-experienced + BETi-naïve n ≈ 130 |
| NCT04817007 | BMS-986158 monotherapy, ± RUX or FEDR | BET inhibition ± JAK inhibition | 1b/2 | n ≈ 192 |
| Signaling pathways | ||||
| NCT04176198 | TP-3654 | PIM inhibition | 1/2 | JAKi-experienced, RUX-, FEDR-ineligible n ≈ 50 |
| NCT04655118 (TL 895-201) | TL-895 | BTX and BMX inhibition | 2 | JAKi ineligible, resistant, relapsed or intolerant n = 149 |
| NCT05280509 | TL-895 + RUX | BTX and BMX inhibition + JAK inhibition | 1b/2 | JAKi-naïve and RUX subobtimal responders n = 70 |
| NCT04640532 (KRT-232-113) | TL-895 ± Navtemadlin | BTX and BMX inhibition ± MDM2 inhibition | 1/2 | JAKi-experienced n ≈ 116 |
| NCT04218071 (Actuate 1901) | 9-ING-41 ± RUX | GSK-3β inhibitor ± JAK inhibition | 2 | RUX-naïve and -experienced n ≈ 58 |
| NCT04543279 | Fostamatinib ± RUX | SYK inhibition ± JAK inhibition | 2 | Severe thrombocytopenia n = 12 |
| NCT03373877 | PU-H71 + RUX | HSP90/epichaperome inhibition + JAK inhibition | 1 | RUX-experienced n ≈ 24 |
| Monoclonal antibody | ||||
| NCT04517851 | Elotuzumab | SLAMF7-targeting | 2 | Not candidate to JAKi n = 15 |
| Target ClinicalTrials.gov identifier . | Molecule . | Mechanism of action . | Phase . | Population on study . |
|---|---|---|---|---|
| Apoptosis | ||||
| NCT04562870 | Selinexor | Selective inhibition of nuclear export | 2 | JAK1/2i-experienced n ≈ 112 |
| NCT03627403 (ESSENTIAL) | Selinexor | Selective inhibition of nuclear export | 2 | JAK1/2i-experienced n ≈ 56 |
| NCT04562389 | Selinexor + RUX | Selective inhibition of nuclear export + JAK inhibition | 1/2 | JAKi-naïve n ≈ 237 |
| Microenvironment | ||||
| NCT03895112 | AVID200 | TGFβ1/3 trap | 1 | RUX-experienced and RUX-ineligible n = 22 |
| NCT04676529 | PXS-5505 | Pan LOX inhibition | 1/2a | RUX/FEDR-naïve and RUX/FEDR -experienced n ≈ 24 |
| NCT04679870 | GB2064 | LOXL-2 inhibition | 2a | JAKi-naïve and JAKi-experienced n ≈ 21 |
| NCT05467800 (MPN-RC 122) | Canakinumab | IL-1β targeting | 2 | RUX/FEDR ineligible, resistant, relapsed or intolerant n = 26 |
| NCT05037760 (KER050-MF-301) | KER050 ± RUX | ActRIIA ligand trap ± JAK inhibition | 2 | JAKi experienced or ineligible (monotherapy) or in stable RUX dose (combination) n = 110 |
| NCT04455841 | INCB000928 ± RUX | ALK2 inhibition ± JAK inhibition | 1/2 | RUX-experienced or ineligible (monotherapy) or in stable RUX dose (combination) n ≈ 100 TD or symptomatic anemia |
| NCT05320198 | DISC-0974 | Hemojuvelin targeting | 1b/2a | Patients with anemia JAKi-naïve and JAKi-experienced n = 56 |
| Epigenetics | ||||
| NCT04480086 | Mivebresib monotherapy, ± RUX or ± navitoclax | BET inhibition ± JAK inhibition ± BCL inhibition | 1b | JAKi-naïve or JAKi-experienced + BETi-naïve n ≈ 130 |
| NCT04454658 | ABBV-744 monotherapy, ± RUX or ± navitoclax | BET inhibition ± JAK inhibition ± BCL inhibition | 1b | JAKi-naïve or JAKi-experienced + BETi-naïve n ≈ 130 |
| NCT04817007 | BMS-986158 monotherapy, ± RUX or FEDR | BET inhibition ± JAK inhibition | 1b/2 | n ≈ 192 |
| Signaling pathways | ||||
| NCT04176198 | TP-3654 | PIM inhibition | 1/2 | JAKi-experienced, RUX-, FEDR-ineligible n ≈ 50 |
| NCT04655118 (TL 895-201) | TL-895 | BTX and BMX inhibition | 2 | JAKi ineligible, resistant, relapsed or intolerant n = 149 |
| NCT05280509 | TL-895 + RUX | BTX and BMX inhibition + JAK inhibition | 1b/2 | JAKi-naïve and RUX subobtimal responders n = 70 |
| NCT04640532 (KRT-232-113) | TL-895 ± Navtemadlin | BTX and BMX inhibition ± MDM2 inhibition | 1/2 | JAKi-experienced n ≈ 116 |
| NCT04218071 (Actuate 1901) | 9-ING-41 ± RUX | GSK-3β inhibitor ± JAK inhibition | 2 | RUX-naïve and -experienced n ≈ 58 |
| NCT04543279 | Fostamatinib ± RUX | SYK inhibition ± JAK inhibition | 2 | Severe thrombocytopenia n = 12 |
| NCT03373877 | PU-H71 + RUX | HSP90/epichaperome inhibition + JAK inhibition | 1 | RUX-experienced n ≈ 24 |
| Monoclonal antibody | ||||
| NCT04517851 | Elotuzumab | SLAMF7-targeting | 2 | Not candidate to JAKi n = 15 |
BETi, BET-inhibitor; FEDR, fedratinib; JAKi, JAK inhibitor; RUX, ruxolitinib; TD, transfusion-dependent.